You are here
Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
J Clin Oncol 32:5s, 2014 (suppl; abstr 7011^)
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).
Background: Idelalisib (IDELA) is a potent and selective inhibitor of PI3Kδ, which is critical for activation, proliferation and survival of B cells and their homing and retention in lymphoid tissues. An unmet need exists for effective therapies in patients with CLL positive for del(17p) and other adverse prognostic factors. This report describes the efficacy of IDELA in combination with rituximab (R) in such high-risk relapsed patients. Methods: Samples for del(17p), del(11q), TP53mut, IGHVmut, ZAP70 and CD38 expression, and β2-microglobulin were collected prospectively and tested using standard methods. Patients were stratified based on presence of del(17p) and/or TP53mut, and on IGHV mutational status. The endpoints evaluated in the high-risk subpopulations in the preplanned 1st interim analysis include progression-free-survival (PFS) and overall response rate (ORR). The primary study analysis was reported in NEJM 2014. Results: IDELA+R retained robust efficacy across all high-risk subpopulations (see Table). Importantly, IDELA+R achieved 76.5% ORR and PFS HR 0.13 in the highest risk patients who were positive for both del(17p) and TP53mut, compared to 80.4% ORR and PFS HR 0.17 in those who had neither present. Conclusions: These results confirm the retained robust efficacy of IDELA in high-risk CLL subpopulations and support IDELA as a potentially important novel treatment for patients with CLL positive for del(17p) and other adverse prognostic factors. Clinical trial information: NCT01539512.
|Rai stage III or IV||0.12||0.05,0.27||52||75.0||60||11.7|
|Binet Stage C||0.13||0.06,0.30||47||74.5||51||13.7|
|Del(17p) and/or TP53mut|
|: Either one alone||0.09||0.02,0.42||20||85.0||24||12.5|
|β2-microglobulin > 4mg/L||0.14||0.07,0.27||75||77.3||68||10.3|
Abstracts by Jeff Porter Sharman:
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).
Effect of clinical NGS-based cancer genomic profiling on physician treatment decisions in advanced solid tumors.
Presentations by Jeff Porter Sharman:
Meeting: 2012 ASCO Annual Meeting
Abstract No: 3069
Session: Developmental Therapeutics - Experimental Therapeutics (General Poster Session)
Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial.Session: Leukemia, Myelodysplasia, and Transplantation (Poster Highlights Session)
Meeting: 2014 ASCO Annual Meeting
Abstract No: 7007
Session: Leukemia, Myelodysplasia, and Transplantation (Oral Abstract Session)